Is Halving Maintenance of Voriconazole Safe and Efficient in Patients Suffering from Invasive Fungal Infections with Serious Hepatic Dysfunction?

References

• Wang T, Yan M, Tang D, et al. Therapeutic drug monitoring and safety of voriconazole therapy in patients with Child–Pugh class B and C cirrhosis: a multicenter study. Int J Infect Dis. 2018;72:49–54. doi:10.1016/j.ijid.2018.05.009
   PubMed Web of Science ®Google Scholar
• Patterson TF, Thompson GR III, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;63:e1–e60. doi:10.1093/cid/ciw326
   PubMed Web of Science ®Google Scholar
• Ashbee HR, Barnes RA, Johnson EM, et al. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British society for medical mycology. J Antimicrob Chemother. 2014;69:1162–1176. doi:10.1093/jac/dkt508
   PubMed Web of Science ®Google Scholar
• Driscoll TA, Yu LC, Frangoul H, et al. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults. Antimicrob Agents Chemother. 2011;55(12):5770–5779. doi:10.1128/AAC.00531-11
   PubMed Web of Science ®Google Scholar
• Alffenaar J-W, Devos T, Uges DA, et al. High voriconazole trough levels in relation to hepatic function: how to adjust the dosage? Br J Clin Pharmacol. 2009;67:262. doi:10.1111/j.1365-2125.2008.03315.x
   PubMed Web of Science ®Google Scholar
• Zhao Y, Hou J, Xiao Y, et al. Predictors of voriconazole trough concentrations in patients with Child–Pugh Class C cirrhosis: a prospective study. Antibiotics. 2021;10:1130.
   Google Scholar
• Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium. Clin Infect Dis. 2020;71:1367–1376. doi:10.1093/cid/ciz1008
   PubMed Web of Science ®Google Scholar
• Li Z-W, Peng F-H, Yan M, et al. Impact of CYP2C19 genotype and liver function on voriconazole pharmacokinetics in renal transplant recipients. Ther Drug Monit. 2017;39:422. doi:10.1097/FTD.0000000000000425
   PubMed Web of Science ®Google Scholar
• Jin H, Wang T, Falcione BA, et al. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis. J Antimicrob Chemother. 2016;71:1772–1785. doi:10.1093/jac/dkw045
   PubMed Web of Science ®Google Scholar
• Luong M-L, Al-Dabbagh M, Groll AH, et al. Utility of voriconazole therapeutic drug monitoring: a meta-analysis. J Antimicrob Chemother. 2016;71:1786–1799. doi:10.1093/jac/dkw099
   PubMed Web of Science ®Google Scholar
• Tan K, Brayshaw N, Tomaszewski K, et al. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol. 2006;46(2):235–243. doi:10.1177/0091270005283837
   PubMed Web of Science ®Google Scholar
• Bajaj JS, O’Leary JG, Tandon P, et al. Nosocomial infections are frequent and negatively impact outcomes in hospitalized patients with cirrhosis. Am J Gastroenterol. 2019;114:1091. doi:10.14309/ajg.0000000000000280
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Y, Zhang J, et al. The application of voriconazole in 76 patients with cirrhosis at Child-Pugh C stage complicated by invasive fungal infection. Zhonghua Gan Zang Bing Za Zhi. 2021;29:137–142. doi:10.3760/cma.j.cn501113-20190813-00302
   PubMedGoogle Scholar
• Johnson H, Han K, Capitano B, et al. Voriconazole pharmacokinetics in liver transplant recipients. Antimicrob Agents Chemother. 2010;54:852–859. doi:10.1128/AAC.00429-09
   PubMed Web of Science ®Google Scholar
• Gao J, Zhang Q, Wu Y, et al. Improving survival of acute-on-chronic liver failure patients complicated with invasive pulmonary aspergillosis. Sci Rep. 2018;8:1–8. doi:10.1038/s41598-017-17765-5
   PubMed Web of Science ®Google Scholar
• Brecher ME. Plasma exchange: why we do what we do. J Clin Apher. 2002;17:207–211. doi:10.1002/jca.10041
   PubMed Web of Science ®Google Scholar
• Guillevin L. Synchronization of plasma exchange and adjuvant treatments. Transfus Sci. 1998;19:27–33. doi:10.1016/S0955-3886(98)00006-X
   PubMedGoogle Scholar
• Smith JW, Weinstein R, For the AABB Hemapheresis Committee. Therapeutic apheresis: a summary of current indication categories endorsed by the AABB and the American society for apheresis. Transfusion. 2003;43(6):820–822. doi:10.1046/j.1537-2995.2003.00397.x
   PubMed Web of Science ®Google Scholar
• Fauvelle F, Petitjean O, Tod M, et al. Clinical pharmacokinetics during plasma exchange. Therapie. 2000;55(2):269–275.
   PubMed Web of Science ®Google Scholar
• Kintzel PE, Eastlund T, Calis KA. Extracorporeal removal of antimicrobials during plasmapheresis. J Clin Apher. 2003;18(4):194–205. doi:10.1002/jca.10074
   PubMed Web of Science ®Google Scholar
• Spriet I, Brüggemann RJ, Annaert P, et al. Pharmacokinetic profile of voriconazole in a critically ill patient on therapeutic plasma exchange. Ther Drug Monit. 2013;35:141–143. doi:10.1097/FTD.0b013e31827d76b0
   PubMed Web of Science ®Google Scholar
• Liang Z, Yu M, Liu Z, et al. Inflammation affects liver function and the metabolism of voriconazole to voriconazole-N-oxide in adult and elderly patients. Front Pharmacol. 2022;13:835871. doi:10.3389/fphar.2022.835871
   PubMed Web of Science ®Google Scholar
• Jager NG, van Hest RM, Lipman J, et al. Therapeutic drug monitoring of anti-infective agents in critically ill patients. Expert Rev Clin Pharmacol. 2016;9:961–979. doi:10.1586/17512433.2016.1172209
   PubMed Web of Science ®Google Scholar
• Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37:840–851. doi:10.1097/CCM.0b013e3181961bff
   PubMed Web of Science ®Google Scholar
• Yamada T, Imai S, Koshizuka Y, et al. Necessity for a significant maintenance dosage reduction of voriconazole in patients with severe liver cirrhosis (Child-Pugh class C). Biol Pharm Bull. 2018. doi:10.1248/bpb.b18-00164
   Web of Science ®Google Scholar